5:20 PM
 | 
Jun 09, 2009
 |  BC Extra  |  Company News

ODAC to discuss Yondelis

FDA's Oncologic Drugs Advisory Committee will meet on July 15 to discuss an NDA from Johnson & Johnson (NYSE:JNJ) for Yondelis trabectedin in combination with

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >